Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FGF13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGF13 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW. |
View FGF13 Products |
| Gene Delivery | FGF13 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Sequence Verified. |
View FGF13 Products |
| Benchmark Ab | Anti-FGF13 Recombinant Antibody Recombinant positive control for assay validation. Sequence Verified. |
View FGF13 Products |
| Validator | FGF13 siRNA Set For knockdown verification in functional assays. |
View FGF13 Products |
| Related Target A | SCN9A (Nav1.7) Primary functional partner of FGF13 in nociceptive neurons; critical for pain pathways. |
View SCN9A Products |
| Related Target B | SCN5A (Nav1.5) Cardiac sodium channel; essential for cardiac counter-screening to avoid arrhythmia risks. |
View SCN5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) | High-purity (>95%) recombinant FGF13 with precise tag options (GST/His) for robust pull-down and TR-FRET assays. |
| Cardiac Safety Counter-Screening (Nav1.5) | Lentivirus premade particles for SCN5A stable cell line generation to evaluate off-target electrophysiological effects. |
| Lack of Controls | Sequence-verified clinical benchmark recombinant antibodies included. |
| False Positives | Validated siRNA sets included for target specificity and knockdown verification. |
Live FGF13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FGF13 therapeutics is intensifying, with major players shifting focus from traditional extracellular FGF pathways to intracellular fibroblast growth factor homologous factors (FHFs). As first-generation pain therapies targeting voltage-gated sodium channels face selectivity challenges, the next wave of R&D is targeting the intracellular FGF13-Nav macromolecular complex to achieve non-addictive pain relief and overcome chemotherapy resistance in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (PPI) | Academic Consortia, Biotech Startups | Neuropathic Pain, Arrhythmia | In vitro binding assays (Need high-purity FGF13 and SCN9A C-terminal peptide) |
| RNA Therapeutics (ASO/siRNA) | Alnylam, Ionis Partners | Platinum-Resistant Ovarian Cancer | In vitro knockdown verification (Need validated FGF13 siRNA and qPCR controls) |
| Gene Therapy / Vector Delivery | Gene Therapy Biotechs | Chronic Pain, Epilepsy | Overexpression validation (Need sequence-verified Lentivirus for stable expression) |